News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
224,617 Results
Type
Article (5018)
Company Profile (17)
Press Release (219582)
Section
Business (82205)
Career Advice (461)
Deals (15041)
Drug Delivery (8)
Drug Development (19065)
Employer Resources (30)
FDA (3674)
Job Trends (3900)
News (120108)
Policy (7498)
Tag
2024 BioCapital Digital (2)
2024 Biotech Beach Standard (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (293)
Adcomms (3)
Allergies (9)
Alliances (14760)
ALS (18)
Alzheimer's disease (241)
Antibody-drug conjugate (ADC) (10)
Approvals (3688)
Artificial intelligence (39)
Autoimmune disease (2)
Automation (2)
Bankruptcy (97)
Best Places to Work (2862)
Biosimilars (11)
Biotechnology (21)
Bladder cancer (9)
Brain cancer (7)
Breast cancer (45)
Cancer (419)
Cardiovascular disease (19)
Career advice (391)
Career pathing (2)
CAR-T (29)
Cell therapy (100)
Cervical cancer (2)
Clinical research (15989)
Collaboration (161)
Compensation (144)
Complete response letters (2)
COVID-19 (301)
CRISPR (7)
C-suite (88)
Cystic fibrosis (16)
Data (478)
Depression (5)
Diabetes (37)
Diagnostics (2035)
Digital health (3)
Diversity, equity & inclusion (12)
Drug discovery (15)
Drug pricing (6)
Drug shortages (1)
Duchenne muscular dystrophy (11)
Earnings (40679)
Editorial (1)
Employer branding (6)
Employer resources (31)
Events (37634)
Executive appointments (277)
FDA (3903)
Featured Employer (6)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (173)
Gene editing (15)
Generative AI (2)
Gene therapy (43)
GLP-1 (103)
Government (407)
Guidances (16)
Healthcare (5036)
Huntington's disease (1)
IgA nephropathy (2)
Immunology and inflammation (13)
Indications (6)
Infectious disease (316)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (15)
Interviews (53)
IPO (7814)
IRA (3)
Job creations (1120)
Job search strategy (360)
Kidney cancer (6)
Labor market (4)
Layoffs (101)
Leadership (4)
Legal (2330)
Liver cancer (17)
Lung cancer (50)
Lymphoma (25)
Management (10)
Manufacturing (45)
MASH (26)
Medical device (3854)
Medtech (3855)
Mergers & acquisitions (7416)
Metabolic disorders (111)
Multiple sclerosis (8)
NASH (6)
Neurodegenerative disease (8)
Neuropsychiatric disorders (1)
Neuroscience (326)
NextGen: Class of 2025 (1674)
Non-profit (727)
Northern California (857)
Now hiring (2)
Obesity (50)
Opinion (30)
Ovarian cancer (17)
Pain (12)
Pancreatic cancer (13)
Parkinson's disease (20)
Partnered (4)
Patents (21)
Patient recruitment (26)
Peanut (5)
People (24503)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase I (4766)
Phase II (6942)
Phase III (5533)
Pipeline (485)
Policy (4)
Postmarket research (626)
Preclinical (1863)
Press Release (66)
Prostate cancer (26)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (63)
Real estate (1872)
Recruiting (8)
Regulatory (5090)
Reports (14)
Research institute (300)
Resumes & cover letters (68)
Rett syndrome (2)
Schizophrenia (20)
Series A (25)
Series B (21)
Sickle cell disease (7)
Southern California (660)
Special edition (1)
Spinal muscular atrophy (28)
Sponsored (3)
Startups (1009)
Stomach cancer (1)
Supply chain (10)
United States (6581)
Vaccines (34)
Venture capitalists (2)
Webinars (4)
Weight loss (19)
Women's health (1)
Date
Today (47)
Last 7 days (207)
Last 30 days (838)
Last 365 days (10288)
2025 (2396)
2024 (11034)
2023 (13201)
2022 (18660)
2021 (19679)
2020 (18238)
2019 (13206)
2018 (10205)
2017 (10001)
2016 (9156)
2015 (12120)
2014 (9587)
2013 (7707)
2012 (8331)
2011 (8796)
2010 (8635)
Location
Africa (183)
Alabama (13)
Alaska (2)
Arizona (58)
Arkansas (1)
Asia (11427)
Australia (1599)
California (1798)
Canada (661)
China (66)
Colorado (76)
Connecticut (90)
Delaware (27)
Europe (24405)
Florida (251)
Georgia (32)
Idaho (23)
Illinois (108)
India (5)
Indiana (59)
Iowa (1)
Japan (63)
Kansas (24)
Kentucky (10)
Louisiana (5)
Maine (38)
Maryland (214)
Massachusetts (1440)
Michigan (84)
Minnesota (133)
Mississippi (1)
Missouri (21)
Montana (16)
Nebraska (12)
Nevada (22)
New Hampshire (15)
New Jersey (528)
New Mexico (5)
New York (446)
North Carolina (312)
North Dakota (2)
Northern California (857)
Ohio (53)
Oklahoma (5)
Oregon (3)
Pennsylvania (328)
Rhode Island (11)
South America (275)
South Carolina (4)
Southern California (660)
Tennessee (34)
Texas (212)
Utah (57)
Virginia (39)
Washington D.C. (8)
Washington State (157)
West Virginia (2)
Wisconsin (20)
224,617 Results for "adolor corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 NANS Annual Meeting
February 4, 2025
·
4 min read
BioMidwest
Adolore BioTherapeutics to Present at the Virtual Investor Pitch Conference
Adolore BioTherapeutics, a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 10:00 AM ET.
June 10, 2024
·
1 min read
Adolore BioTherapeutics Outlines Strategy for its Next Generation, Disease-Modifying, Non-Opioid Analgesic Gene Therapies for the Treatment of Chronic Pain
Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today outlined recent pipeline development progress and provided a business outlook.
May 21, 2024
·
7 min read
Press Releases
Adolore BioTherapeutics to Present at BioSparkVA Pitch Event
September 25, 2024
·
3 min read
Press Releases
Adolore BioTherapeutics to Present at 18th Annual Pain Therapeutics Summit
October 2, 2024
·
3 min read
Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference
Adolore BioTherapeutics (“Adolore” or the “Company”), a company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roelof Rongen, CEO of Adolore, will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 3:00 PM ET.
October 11, 2023
·
2 min read
Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting
Adolore BioTherapeutics (“Adolore” or the “Company”) today announced that Roy C. Levitt, MD, the Company’s founder and Executive Chairman, Clinical Professor, University of Miami, and Principal Investigator of a NIH, NINDS, HEAL UH3 Award will present at the 5th Annual NIH HEAL Initiative Scientific Meeting being held February 7-8, 2024 in Bethesda, Maryland.
January 30, 2024
·
4 min read
Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain
Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced the U.S. Patent and Trademark Office (USPTO) has issued patent No. 11,911,450 covering its innovative CA8* (*Carbonic anhydrase-8-like analgesic peptides, CA8 variants) gene therapies, using a state-of-the-art replication-defective disease-free HSV vector (rdHSV-CA8*).
March 4, 2024
·
5 min read
BioMidwest
Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels
Adolore BioTherapeutics announced the publication of its manuscript titled, " rdHSV-CA8 non-opioid analgesic gene therapy decreases somatosensory neuronal excitability by activating Kv7 voltage-gated potassium channels,[1]” in the peer-reviewed journal, Frontiers in Molecular Neuroscience.
May 16, 2024
·
6 min read
Adolore Biotherapeutics to Participate in the Virtual Investor Summer Spotlight Series
Adolore Biotherapeutics today announced that Roelof Rongen, CEO and Roy Levitt, MD, Founder and Executive Chairman of Adolore, will participate in the Virtual Investor Summer Spotlight Series on Tuesday, July 11, 2023.
July 5, 2023
·
1 min read
1 of 22,462
Next